首页>投融资
天辰生物
B+轮
天辰生物致力于在自身免疫疾病领域研发具有差异化的新一代大分子抗体。公司研发管线聚焦自身免疫领域尚未满足的临床需求，有多个品种正在稳步推进。利用公司的技术平台：抗体发现平台、抗体工程平台和工艺开发平台，公司未来将持续推进和丰富研发管线，为患者带来更多临床获益。
基本信息
-
公司全称天辰生物医药（苏州）有限公司
-
类型创新型药物研发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址常熟市东南大道33号科创大厦A区601室
-
联系电话021-58372390
-
邮箱978779631@qq.com
-
成立时间2020-10-25
投融资
-
2024-09-24B+轮数亿人民币启明创投
-
2023-10-31B轮超亿元人民币常熟吴越天使创投合肥弘沓山证创投湖州友成中小企业发展基金交子创投
-
2023-10-31B轮1.12亿人民币东方富海山西证券常熟国发创投上海通锐投资瑞城创投
-
2022-09-27A+轮未透露永石资本
-
2022-09-27A+轮未透露永石投资
-
2022-08-17A+轮数千万人民币未透露
-
2022-08-17A+轮数千万人民币上海通锐投资
-
2021-01-04A轮超亿元人民币仙瞳资本常熟创投东方富海永石资本
-
2021-01-04A轮数亿人民币常熟东南产业投资仙瞳资本东方富海石丰昕汇深圳市新生华创永石投资安诚资本奋毅资本
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息